Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.
You may also be interested in...
Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.
The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.